Get started
Author

Meike Hutt

Observed names: Hutt, Meike, M. Hutt
ORCID: 0000-0002-5696-2140
Observed ORCID: 0000-0002-5696-2140
OpenAlex ID: A5033225713
Pharmacokinetic properties of IgG and various Fc fusion proteins in mice
2015 · Felix Unverdorben, Fabian Richter, et al. · mAbs · 119
PDF
Plasma Half-life Extension of Small Recombinant Antibodies by Fusion to Immunoglobulin-binding Domains
2011 · Meike Hutt, Aline Färber-Schwarz, et al. · Journal of Biological Chemistry · 79
Quantitative immunopeptidomics reveals a tumor stroma–specific target for T cell therapy
2022 · Gloria B. Kim, Jens Fritsche, et al. · Science Translational Medicine · 41
PDF
Superior Properties of Fc-comprising scTRAIL Fusion Proteins
2017 · Meike Hutt, Lisa Marquardt, et al. · Molecular Cancer Therapeutics · 41
An optimized antibody-single-chain TRAIL fusion protein for cancer therapy
2016 · Martin Siegemund, Oliver Seifert, et al. · mAbs · 36
PDF
Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A
2012 · F. Unverdorben, A. Farber-Schwarz, et al. · Protein Engineering Design and Selection · 29
IgG-single-chain TRAIL fusion proteins for tumour therapy
2018 · Martin Siegemund, Felix Schneider, et al. · Scientific Reports · 28
PDF
Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV
2017 · Lisa C. Schmitt, Alexander Rau, et al. · mAbs · 25
PDF
Convergence of pathway analysis and pattern recognition predicts sensitization to latest generation TRAIL therapeutics by IAP antagonism
2020 · Vesna Vetma, Cristiano Guttà, et al. · Cell Death and Differentiation · 24
PDF
A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties
2015 · Felix Unverdorben, Meike Hutt, et al. · PLoS ONE · 22
PDF
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells
2018 · Meike Hutt, Sina Fellermeier-Kopf, et al. · Oncotarget · 18
PDF
Antitumor Activity of a Mesenchymal Stem Cell Line Stably Secreting a Tumor-Targeted TNF-Related Apoptosis-Inducing Ligand Fusion Protein
2017 · Irene Marini, Martin Siegemund, et al. · Frontiers in Immunology · 16
PDF
An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions
2023 · Stefan Krämer, Andreas Moritz, et al. · Scientific Reports · 10
PDF
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
2026 · Martin Wermke, Sebastian Ochsenreither, et al. · Nature Medicine · 8
PDF
Effective Targeting of PRAME-Positive Tumors with Bispecific T Cell-Engaging Receptor (TCER®) Molecules
2019 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 7
Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanoma
2018 · Greta Del Mistro, Philippe Lucarelli, et al. · npj Systems Biology and Applications · 7
PDF
1001MO Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR bispecific, in phase I dose escalation
2024 · M. Wermke, S. Ochsenreither, et al. · Annals of Oncology · 4
PDF
IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME
2022 · Sebastian Bunk, Martin Hofmann, et al. · Blood · 4
753P Targeting solid tumors with IMA402, a next-generation bispecific T cell engaging receptor against PRAME
2022 · S. Missel, S. Bunk, et al. · Annals of Oncology · 4
Molecular modelling of the mass density of single proteins
2012 · Meike Hutt, Tobias Kulschewski, et al. · Journal of Biomolecular Structure and Dynamics · 4
PDF
1319 Next-generation TCR bispecifics (TCER®) targeting peptide-HLA antigens for the treatment of patients with solid tumors
2022 · Sebastian Bunk, Martin Hofmann, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 2789: Development of highly potent T-cell receptor bispecifics with picomolar activity against tumor-specific HLA ligands
2018 · Sebastian Bunk, Martin Hofmann, et al. · Cancer Research · 2
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
2026 · Martin Wermke, Sebastian Ochsenreither, et al. · Nature Medicine · 1
PDF
Generation of a highly versatile TCR bispecific scaffold optimized for targeting tumor-specific peptide-HLA antigens
2026 · Martin Hofmann, Felix Unverdorben, et al. · mAbs
PDF
Supplementary Figure 6 from Superior Properties of Fc-comprising scTRAIL Fusion Proteins
2023 · Meike Hutt, Lisa Marquardt, et al.
PDF
Works count: 41
Citation count: 531
H-index: 12
I10-index: 13
Year
Topic
Type